Ono Pharmaceutical has entered into a drug discovery collaboration with Reborna Biosciences to develop novel small molecules targeting ribonucleic acid (RNA) for the treatment of central nervous system disorders.
Reborna’s drug discovery platform incorporates proprietary screening technology that analyses predicted three-dimensional RNA structures within the human body.
This approach enables the identification of small molecule compounds capable of modulating RNA functions, an area traditionally challenging for conventional drug discovery methods.
Through this partnership, the companies will leverage Reborna’s proprietary RNA-targeting drug discovery platform to identify small molecule compounds with potential therapeutic applications for rare neurological conditions. Ono will have an exclusive option to develop, manufacture, and commercialise these compounds globally.
As part of the agreement, Reborna will receive an upfront payment, research funding, milestone payments linked to development progress and sales, as well as tiered royalties based on net sales.
This collaboration aligns with Ono’s focus on advancing innovative treatments for complex neurological conditions, aiming to address unmet medical needs and enhance therapeutic options for patients.